| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1277 | 2019 |
| Pan-cancer whole-genome analyses of metastatic solid tumours P Priestley, J Baber, MP Lolkema, N Steeghs, E de Bruijn, C Shale, ... Nature 575 (7781), 210-216, 2019 | 836 | 2019 |
| Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors KM Heinhuis, W Ros, M Kok, N Steeghs, JH Beijnen, JHM Schellens Annals of Oncology 30 (2), 219-235, 2019 | 428 | 2019 |
| Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and … J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, ... Journal of Clinical Oncology 39 (4), 273-284, 2021 | 353 | 2021 |
| Pervasive chromosomal instability and karyotype order in tumour evolution TBK Watkins, EL Lim, M Petkovic, S Elizalde, NJ Birkbak, GA Wilson, ... Nature 587 (7832), 126-132, 2020 | 291 | 2020 |
| The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies L Angus, M Smid, SM Wilting, J van Riet, A Van Hoeck, L Nguyen, ... Nature genetics 51 (10), 1450-1458, 2019 | 285 | 2019 |
| Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology RB Verheijen, H Yu, JHM Schellens, JH Beijnen, N Steeghs, ... Clinical Pharmacology & Therapeutics 102 (5), 765-776, 2017 | 268 | 2017 |
| Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets H Yu, N Steeghs, CM Nijenhuis, JHM Schellens, JH Beijnen, ... Clinical pharmacokinetics 53, 305-325, 2014 | 259 | 2014 |
| The mutational footprints of cancer therapies O Pich, F Muiños, MP Lolkema, N Steeghs, A Gonzalez-Perez, ... Nature genetics 51 (12), 1732-1740, 2019 | 256 | 2019 |
| Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor N Steeghs, H Gelderblom, J Roodt, O Christensen, P Rajagopalan, ... Clinical Cancer Research 14 (11), 3470-3476, 2008 | 243 | 2008 |
| Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments N Steeghs, JWR Nortier, H Gelderblom Annals of surgical oncology 14, 942-953, 2007 | 185 | 2007 |
| A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns W Jiao, G Atwal, P Polak, R Karlic, E Cuppen, A Danyi, J de Ridder, ... Nature communications 11 (1), 728, 2020 | 183 | 2020 |
| Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis A Kollár, RL Jones, S Stacchiotti, H Gelderblom, M Guida, G Grignani, ... Acta oncologica 56 (1), 88-92, 2017 | 177 | 2017 |
| Therapeutic drug monitoring of oral targeted antineoplastic drugs A Mueller-Schoell, SL Groenland, O Scherf-Clavel, M van Dyk, ... European journal of clinical pharmacology 77, 441-464, 2021 | 166 | 2021 |
| The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact LF van Dessel, J van Riet, M Smits, Y Zhu, P Hamberg, ... Nature communications 10 (1), 5251, 2019 | 165 | 2019 |
| Molecular tumor boards: current practice and future needs DL Van der Velden, CML Van Herpen, HWM Van Laarhoven, EF Smit, ... Annals of Oncology 28 (12), 3070-3075, 2017 | 150 | 2017 |
| Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. F Meric-Bernstam, SK Sandhu, O Hamid, A Spreafico, S Kasper, ... Journal of Clinical Oncology 37 (15_suppl), 2507-2507, 2019 | 144 | 2019 |
| Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors N Steeghs, FALM Eskens, H Gelderblom, J Verweij, JWR Nortier, ... Journal of Clinical Oncology 27 (30), 5094-5101, 2009 | 123 | 2009 |
| Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care NAG Lankheet, LM Knapen, JHM Schellens, JH Beijnen, N Steeghs, ... Therapeutic drug monitoring 36 (3), 326-334, 2014 | 113 | 2014 |
| Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours NAG Lankheet, JSL Kloth, CGM Gadellaa-van Hooijdonk, GA Cirkel, ... British journal of cancer 110 (10), 2441-2449, 2014 | 112 | 2014 |
